JP2017504595A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504595A5 JP2017504595A5 JP2016539167A JP2016539167A JP2017504595A5 JP 2017504595 A5 JP2017504595 A5 JP 2017504595A5 JP 2016539167 A JP2016539167 A JP 2016539167A JP 2016539167 A JP2016539167 A JP 2016539167A JP 2017504595 A5 JP2017504595 A5 JP 2017504595A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- pharmaceutically acceptable
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000004452 carbocyclyl group Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 125000003107 substituted aryl group Chemical group 0.000 claims 18
- 239000013078 crystal Substances 0.000 claims 17
- 239000000651 prodrug Substances 0.000 claims 17
- 229940002612 prodrug Drugs 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 16
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000012526 B-cell neoplasm Diseases 0.000 claims 1
- 101100273739 Homo sapiens CD68 gene Proteins 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036917P | 2014-08-13 | 2014-08-13 | |
| US62/036,917 | 2014-08-13 | ||
| PCT/US2014/070167 WO2015089481A2 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504595A JP2017504595A (ja) | 2017-02-09 |
| JP2017504595A5 true JP2017504595A5 (enExample) | 2018-07-26 |
| JP6878004B2 JP6878004B2 (ja) | 2021-05-26 |
Family
ID=53371973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539167A Active JP6878004B2 (ja) | 2013-12-13 | 2014-12-12 | リンパ形質細胞性リンパ腫を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9908872B2 (enExample) |
| EP (1) | EP3079682A4 (enExample) |
| JP (1) | JP6878004B2 (enExample) |
| AU (1) | AU2014361800B2 (enExample) |
| CA (1) | CA2932353A1 (enExample) |
| WO (1) | WO2015089481A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| SG11201805514VA (en) | 2016-01-13 | 2018-07-30 | Stora Enso Oyj | Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof |
| JP2019507179A (ja) | 2016-03-01 | 2019-03-14 | プロペロン セラピューティックス インコーポレイテッド | Ｗｄｒ５タンパク質−タンパク質結合の阻害剤 |
| WO2017147700A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| AU2017363313B2 (en) * | 2016-11-22 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| MA46942A (fr) | 2016-11-30 | 2021-05-05 | Ariad Pharma Inc | Anilinopyrimidines en tant qu'inhibiteurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
| CN111032642B (zh) * | 2017-06-29 | 2023-07-18 | 里格尔药品股份有限公司 | 激酶抑制剂及制造和使用方法 |
| AU2019220632B2 (en) | 2018-02-14 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | IRAK degraders and uses thereof |
| CN108707147A (zh) * | 2018-06-20 | 2018-10-26 | 桑文军 | 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用 |
| CA3224985A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2023183377A1 (en) | 2022-03-23 | 2023-09-28 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) * | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| EP1071658B1 (en) | 1998-04-17 | 2004-06-16 | Parker Hughes Institute | Btk inhibitors and methods for their identification and use |
| US6432949B1 (en) * | 1998-08-04 | 2002-08-13 | Astrazeneca Ab | Amide derivatives useful as inhibitors of the production of cytokines |
| EP1115707B1 (en) * | 1998-09-25 | 2003-11-12 | AstraZeneca AB | Benzamide derivatives and ther use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| MXPA05001804A (es) | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| US8030336B2 (en) | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| WO2006067445A2 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| EP1831198B1 (en) * | 2004-12-22 | 2009-04-08 | AstraZeneca AB | Pyridine carboxamide derivatives for use as anticancer agents |
| CA2593803A1 (en) | 2005-01-26 | 2006-08-03 | Irm Llc | Thiazole-amide compounds and compsitions as protein kinase inhibitors |
| JP5305905B2 (ja) | 2005-08-08 | 2013-10-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チアゾロピリミジンキナーゼ阻害剤 |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| EP1957461B1 (en) * | 2005-11-14 | 2016-11-02 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| SG166093A1 (en) * | 2006-09-22 | 2010-11-29 | Pharmacyclics Inc | Inhibitors of brutonæs tyrosine kinase |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| ES2401557T3 (es) | 2007-08-02 | 2013-04-22 | Amgen, Inc | Moduladores de Pl3 cinasas y métodos de uso |
| EP2537847A1 (en) | 2007-10-23 | 2012-12-26 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| ES2396366T3 (es) | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| KR101403093B1 (ko) * | 2008-08-13 | 2014-06-19 | 미쓰이가가쿠 아그로 가부시키가이샤 | 아미드 유도체, 그 아미드 유도체를 함유하는 유해 생물 방제제 및 그 사용방법 |
| AU2009289378A1 (en) | 2008-09-02 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Novel benzamides, production thereof, and use thereof as medicaments |
| EP2365970B1 (en) | 2008-11-12 | 2018-03-21 | Gilead Connecticut, Inc. | Pyridazinones and their use as btk inhibitors |
| JP5868855B2 (ja) | 2009-09-03 | 2016-02-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | チロシンキナーゼ調節剤としての化合物 |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| JP2014500254A (ja) | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
| EP2640366A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| US9273029B2 (en) * | 2011-05-23 | 2016-03-01 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| SG10201604682VA (en) * | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US9023873B2 (en) * | 2011-10-03 | 2015-05-05 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| US20140235643A1 (en) | 2011-10-04 | 2014-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| BR112014010439A2 (pt) | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| PL2790705T3 (pl) | 2011-12-15 | 2018-06-29 | Novartis Ag | Zastosowanie inhibitorów czynności lub funkcji PI3K |
| CN103405429A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| EP3079682A4 (en) | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
-
2014
- 2014-12-12 EP EP14869351.8A patent/EP3079682A4/en active Pending
- 2014-12-12 CA CA2932353A patent/CA2932353A1/en active Pending
- 2014-12-12 WO PCT/US2014/070167 patent/WO2015089481A2/en not_active Ceased
- 2014-12-12 JP JP2016539167A patent/JP6878004B2/ja active Active
- 2014-12-12 US US15/104,005 patent/US9908872B2/en active Active
- 2014-12-12 AU AU2014361800A patent/AU2014361800B2/en not_active Ceased
-
2018
- 2018-02-23 US US15/904,143 patent/US10597387B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504595A5 (enExample) | ||
| JP2017502006A5 (enExample) | ||
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2017537940A5 (enExample) | ||
| JP2018515434A5 (enExample) | ||
| JP2020509022A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2018522867A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2017512833A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2019514874A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2011518811A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| HRP20161478T1 (hr) | Inhibitori protein kinaze (varijante), njihova upotreba za liječenje neuroloških bolesti, kao i farmaceutski pripravak koji se na njima temelji | |
| JP2014510774A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2016509591A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2010280669A5 (enExample) | ||
| JP2010527985A5 (enExample) |